Toxic epidermal necrolysis and stevens-johnson syndrome in South Africa: A 3-year prospective study

QJM: An International Journal of Medicine

Volumn 105, Issue 9, 2012, Pages 839-846

  Kannenberg, S M H ^a   Jordaan, H F ^a   Koegelenberg, C F N ^a   Von Groote Bidlingmaier, F ^a   Visser, W I ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; COTRIMOXAZOLE; ETHAMBUTOL; ISONIAZID; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ARTICLE; CLINICAL FEATURE; COMORBIDITY; COMPLICATION; DISEASE SEVERITY; EPILEPSY; EVALUATION AND FOLLOW UP; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOALBUMINEMIA; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SKIN DISEASE; SOUTH AFRICA; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TUBERCULOSIS;

EID: 84867113136     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcs078     Document Type: Article

References (33)

1. Pereira F, Mudgil A, Rosmarin D. Toxic epidermal necrolysis. J Am Acad Dermatol 2007; 56:181-200.
2. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129:92-6.
3. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002; 8:5.
4. Bastuji-Garin S, Zahedi M, Guillaume JC, Roujeau JC. Toxic epidermal necrolysis (Lyell syndrome) in 77 elderly patients. Age Ageing 1993; 22:450-6.
5. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333:1600-7.
6. Caumes E, Bossi P, Katlama C, Bricaire F. Antiretroviral induced toxiderma in HIV-infected patients. Presse Med 2003; 32:1325-33.
7. Leone R, Venegoni M, Motola D, Moretti U, Piazzetta V, Cocci A, et al. Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions. Drug Saf 2003; 26:109-20.
8. Todd G. Adverse cutaneous drug eruptions and HIV: a clinician's global perspective. Dermatol Clin 2006; 24:459-72.
9. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115:149-53.
10. Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, Roujeau JC, Revuz J. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126:272-76.
11. Faye O, Wechsler J, Roujeau JC. Cell-mediated immunologic mechanism and severity of TEN. Arch Dermatol 2005; 141:775-6.
12. Karim SS, Churchyard GJ, Karim QA, Lawn SD. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 2009; 374:921-33.
13. World Health Organization report 2008. Global tuberculosis control-surveillance, planning, financing. Geneva, 2008:19 [http://www.who.int/tb/publications/global_report/2008/en/index.html.] Accessed 12 October 2011.
14. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149:818-24.
15. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-55.
16. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care 2004; 8:R204-12.
17. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
18. Rajaratnam R, Mann C, Balasubramaniam P, Marsden JR, Taibjee SM, Shah F, et al. Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre. Clin Exp Dermatol 2010; 35:853-62.
19. Hunt GM, Coovadia A, Abrams EJ, Sherman G, Meyers T, Morris L, et al. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS 2011; 25:1461-9.
20. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167:1472-7.
21. Lehloenya RJ, Todd G, Badri M, Dheda K. Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions. Int J Tuberc Lung Dis 2011; 15:1649-57.
22. Cedeno-Laurent F, Gó mez-Flores M, Mendez N, Ancer-Rodri{dotless}́guez J, Bryant JL, Gaspari AA, et al. New insights into HIV-1-primary skin disorders. Int AIDS Soc 2011; 14:5.
23. Belsito DV, Sanchez MR, Baer RL, Valentine F, Thorbecke GJ. Reduced Langerhans' cell Ia antigen and ATPase activity in patients with the acquired immunodeficiency syndrome. N Engl J Med 1984; 310:1279-82.
24. Tschachler E, Groh V, Popovic M, Mann DL, Konrad K, Safai B, et al. Epidermal Langerhans cells-a target for HTLV-III/LAV infection. J Invest Dermatol 1987; 88:233-7.
25. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol 2003; 139:39-43.
26. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 2004; 140:890-2.
27. Gerdts B, Vloemans AF, Kreis RW. Toxic epidermal necrolysis: 15 years' experience in a Dutch burns centre. J Eur Acad Dermatol Venereol 2007; 21:781-8.
28. Cartotto R, Mayich M, Nickerson D, Gomez M. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. J Burn Care Res 2008; 29:141-6.
29. Sekula P, Liss Y, Davidovici B, Dunant A, Roujeau JC, Kardaun S, et al. Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res 2011; 32:237-45.
30. Westly ED, Wechsler HL. Toxic epidermal necrolysis: granulocytic leukopenia as a prognostic indicator. Arch Dermatol 1984; 120:721-6.
31. Engelhardt SL, Schurr MJ, Helgerson RB. Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage. J Burn Care Rehabil 1997; 18:520-4.
32. Schulz JT, Sheridan RL, Ryan CM, MacKool B, Tompkins RG. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000; 21:199-204.
33. Haber J, Hopman W, Gomez M, Cartotto R. Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil 2005; 26:33-41